Atlas›Domain IX · Biomedical, neuro & digital›Guide 005
Guide IX-005

Anxiolytics

A 24 · L 69 · M 719 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

1. Introduction

Version followed: US FDA class-wide benzodiazepine Boxed Warning (Drug Safety Communication, 23 September 2020); NICE CG113, Generalised anxiety disorder and panic disorder in adults (GAD recommendations 2011, panic recommendations from 2004, amendments to 2022 including the pregabalin recommendation 1.2.25); MHRA Drug Safety Updates on pregabalin (April 2019 and February 2021); current US buspirone labelling. Checked October 2026.

"Anxiolytics" is a group of medicines, not a psychotherapy. These medicines are prescribed and managed by doctors and other licensed prescribers (GPs, psychiatrists, and non-medical prescribers where local law allows). This guide is written for the psychotherapist working alongside the prescriber. It covers what the official labelling and guidelines say, and what the therapist does: psychoeducation, supporting informed choice, watching for warning signs and passing them on, coordinating exposure work, and supporting the client through any prescriber-led change. [source: FDA 2020; NICE CG113]

The medicines covered are: benzodiazepines; pregabalin (NICE's option for GAD when SSRIs and SNRIs are not tolerated); buspirone; and, briefly, the SSRIs and SNRIs that NICE places first among drug options for anxiety. NICE CG113 treats drug treatment as one option within stepped care. At step 3 it offers the person a choice between a high-intensity psychological intervention and drug treatment (1.2.17). [source: NICE CG113 1.2.17, 1.2.23–1.2.27]

How change happens, as the sources frame it: medicines reduce symptoms while they are taken. Learning-based therapy aims to change how the person responds to fear, and those gains need to last once the medicine stops. One study found that patients who credited their improvement to medication rather than their own efforts had more withdrawal symptoms and lost more of their gains after stopping [source: Başoglu et al. 1994]. The therapist's job is to make sure the client's gains are learned and owned by the client, while never advising on the medicine itself. [synthesis]

This guide gives no doses, schedules, combinations or instructions on starting, switching, reducing or stopping any medicine. Benzodiazepine withdrawal can be life-threatening and must be medically supervised. The FDA states that patients should not stop suddenly without first agreeing a plan with their prescriber. Every medication question goes to the prescriber. [source: FDA 2020]

2. Framework

The medicine has no psychotherapy "phases". The framework below describes the psychotherapist's work alongside it. The prescriber's review points, which NICE sets out, are included so the therapist knows when the client will be seen and when reports are most useful. [synthesis, built on NICE CG113]

Phase A: Assessment and orientation (sessions 1–2 of your own protocol).

  • Goals: take a current medication list, including as-needed use, alcohol, opioids (prescribed or not) and other sedatives. Learn the client's beliefs about the medicine, and find out who prescribes and how to reach them. Obtain consent to share information. [synthesis; FDA 2020 asks patients to tell all their health professionals about every medicine and substance they use]
  • Move on when: you know who prescribes, have consent to liaise (or the client has declined it), and have shared a safety plan for emergency signs.

Phase B: Treatment choice and informed consent (when drug treatment is being considered or reviewed).

  • Goals: help the client understand the options NICE describes and bring their own questions to the prescriber. NICE asks prescribers to share information, consider the person's preference and past experience, and address common worries such as fear of addiction. [source: NICE CG113 1.2.44–1.2.46]
  • Move on when: the client has the information they need and the decision rests with them and the prescriber.

Phase C: Early concurrent treatment (first weeks after a prescription starts or changes).

  • Goals: watch for and pass on side effects, activation and suicidality warnings, and support adherence questions. NICE's prescriber review points are: for GAD, every 2–4 weeks for the first 3 months, then every 3 months (1.2.32). For panic disorder, within 2 weeks, then at 4, 6 and 12 weeks (1.3.41). People under 30 starting an SSRI or SNRI should be seen within 1 week and monitored weekly for the first month (1.2.30). [source: NICE CG113]
  • Format: your usual psychotherapy sessions, plus brief written or phone liaison with the prescriber as agreed.

Phase D: Active psychological treatment, including exposure.

  • Goals: deliver CBT or exposure according to its own manual, with an explicit plan for how sedating medicine use is discussed with the prescriber. Watch especially for as-needed use before or during exposure tasks. [synthesis; source on interaction: Başoglu et al. 1994; Rosen et al. 2013]
  • Move on when: the client is attributing gains to their own coping and approaching feared situations without avoidance.

Phase E: Maintenance, or prescriber-led discontinuation.

  • Goals: if the prescriber and client decide to reduce or stop a medicine, the prescriber sets the plan. The therapist offers CBT support, watches for withdrawal signs and helps the client tell withdrawal symptoms apart from relapse. Trials found more successful benzodiazepine discontinuation when CBT was added to a gradual taper. [source: AJP 1993 trial abstract; Takeshima et al. 2021] NICE advises continuing effective drug treatment for GAD and for panic disorder for a period after response, because relapse is likely if it stops too soon (1.2.33, 1.3.27); how long is a decision for the prescriber and client. [source: NICE CG113]

Phase F: After treatment ends. Relapse prevention, a written early-warning plan, and booster sessions. [synthesis]

Typical session count: the length of the psychological treatment follows its own protocol. No session count is set for the therapist's role alongside medication. [uncertain: not specified in the published sources]

3. Guiding principles

  • The prescriber owns the medicine. You never tell, suggest or hint that a client should start, stop, skip, reduce or increase a medicine. You say: "That is a question for your prescriber; let's work out how to ask it." [source: FDA 2020 directs stopping plans to the prescriber; synthesis]
  • Benzodiazepine withdrawal is a medical matter. Withdrawal can be life-threatening and needs medical supervision. Never discuss reduction amounts or speed. [source: FDA 2020]
  • Know the warnings well enough to recognise them. You need to know the boxed and regulator warnings by heart, because you may see the client more often than the prescriber does. [source: FDA 2020; MHRA 2019, 2021; synthesis]
  • Ask about opioids, alcohol and other sedatives every time risk changes. Combining benzodiazepines or pregabalin with opioids, alcohol or other CNS depressants can cause dangerous breathing problems and death. [source: FDA 2020; MHRA 2021]
  • Choice is the client's, informed by both clinicians. NICE gives a choice between psychological and drug treatment at step 3. Support the client's preference; do not lobby either way. [source: NICE CG113 1.2.17, 1.2.45]
  • Psychological treatment is a recommended route in its own right. NICE lists high-intensity psychological intervention as a first-line option. The FDA asks prescribers to consider non-drug alternatives for stress, anxiety and insomnia. [source: NICE CG113; FDA 2020]
  • Gains should belong to the client. Help clients credit their own coping, because crediting the medication predicted relapse in one trial. [source: Başoglu et al. 1994]
  • Collaborate openly. Agree with the client what you will share with the prescriber and when, and keep them informed of every contact. [synthesis]
  • Neutral, curious stance on ambivalence. Explore mixed feelings about medication without trying to resolve them in either direction. Pass the question to the prescriber. [synthesis]
  • Escalate warning signs the same day. Severe withdrawal signs, breathing problems, seizures, confusion, or thoughts of suicide or of harming others call for urgent medical contact or emergency services. [source: FDA 2020]

4. Intervention inventory

Part A gives a factual description of each medicine, as labelling, regulators and NICE state it. It is there so you can recognise risks and follow what the prescriber is doing, not so you can advise. Part B gives the psychotherapist's own interventions.

A1. Benzodiazepines: how they are delivered and what the labelling warns

  • Purpose: know the class, its official warnings and the warning signs you may be first to see.
  • Delivery (descriptive): prescribed by a licensed prescriber. The FDA class list includes alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam and triazolam. Formulations include tablets and, for some products meant for very short-term use, injection, nasal and rectal forms. The FDA notes that these short-term products can also cause withdrawal if used long-term. [source: FDA 2020]
  • US Boxed Warning (2020): the FDA required the Boxed Warning for all benzodiazepines to be updated. It now describes the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions consistently across the class. Changes were also required to the Warnings and Precautions, Drug Abuse and Dependence, and Patient Counseling sections, and to the patient Medication Guides. As the FDA describes them:
    • Abuse and misuse (taking the medicine to get high, or other than prescribed) can lead to overdose or death, especially with opioids, alcohol or illicit drugs.
    • Addiction can occur even at recommended doses.
    • Physical dependence can develop over days to weeks of steady use, even as prescribed.
    • Withdrawal reactions after abrupt stopping or rapid reduction may be life-threatening. [source: FDA 2020]
  • Opioid co-use: in August 2016 the FDA warned of serious risks, including severe respiratory depression and death, when benzodiazepines are combined with opioid pain or cough medicines. In September 2017 it cautioned against withholding opioid addiction medicines from patients who take benzodiazepines or other CNS depressants, and advised careful management instead. [source: FDA 2020, which summarises both]
  • Withdrawal signs the FDA lists for patients: abnormal involuntary movements, anxiety, blurred vision, memory problems, irritability, insomnia, muscle pain and stiffness, panic attacks and tremors. Severe signs that need the prescriber or emergency care: catatonia, seizures, delirium tremens, depression, hallucinations, thoughts of killing oneself or someone else, mania and psychosis. [source: FDA 2020]
  • Protracted withdrawal (FDA, health professional section): symptoms can persist beyond 4–6 weeks and may last up to 12 months. They include anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms, paresthesia and tinnitus. [source: FDA 2020]
  • What the FDA asks prescribers to do (descriptive): assess the risk of abuse, misuse and addiction before and during treatment; limit dose and duration to the minimum needed; reduce or stop only by a gradual, patient-specific plan with monitoring; refer for substance use treatment if a use disorder is suspected; and consider non-drug alternatives. Patients are told to take the medicine only as prescribed, avoid alcohol, lock it away, read the Medication Guide with each prescription, and seek emergency care for trouble breathing or seizures. [source: FDA 2020]
  • NICE position: for GAD, do not offer a benzodiazepine except as a short-term measure during crises (1.2.26). For panic disorder, benzodiazepines should not be prescribed (1.3.20). [source: NICE CG113]
  • PTSD (for clients with comorbid trauma): the 2023 VA/DoD guideline strongly recommends against benzodiazepines for PTSD, according to an August 2025 evidence summary published on health.mil. [source: health.mil 2025; also Steenen et al. 2013, citing VA/DoD and WFSBP guidance]
  • Watch for: the withdrawal and severe signs above; sedation, memory problems or unsteadiness; use above what was prescribed, or obtaining supply from others; alcohol or opioid co-use. [source: FDA 2020]

A2. Pregabalin

  • Purpose: know its place in anxiety care and its UK regulatory warnings.
  • Place in guidelines: NICE says to consider pregabalin for GAD if the person cannot tolerate SSRIs or SNRIs (1.2.25, amended 2022). [source: NICE CG113] Its US licensing status for anxiety is not covered here. [uncertain]
  • Formulation: oral (capsules and other forms). [uncertain: formulation types not detailed here]
  • UK legal status: since 1 April 2019, pregabalin and gabapentin have been Class C controlled drugs under the Misuse of Drugs Act 1971 and Schedule 3 under the Misuse of Drugs Regulations 2001. The reasons were abuse, misuse, diversion and dependence. Possessing either drug without a prescription, or supplying it to others, is illegal. [source: MHRA April 2019]
  • Abuse and dependence: prescribers should check for a history of drug abuse before prescribing and watch for drug-seeking behaviour, dose escalation and tolerance. Taking pregabalin with opioids or alcohol risks potentially fatal respiratory depression and sedation. [source: MHRA 2019]
  • Respiratory depression (MHRA, February 2021): severe respiratory depression has been reported, sometimes without opioids, and most cases were in elderly people. Higher-risk groups: people with compromised respiratory function, respiratory or neurological disease, or renal impairment; people taking other CNS depressants (opioids, benzodiazepines, gabapentin); and people over 65. Signs to watch for: new or increased trouble breathing, breathlessness or shallow breathing, sometimes with sleepiness. Patients are advised to avoid alcohol and contact a doctor promptly about breathing changes. [source: MHRA 2021]
  • Watch for: breathing changes, heavy sedation, requests for early supply, use above what was prescribed, and street or online supply.

A3. Buspirone

  • Purpose: know a non-benzodiazepine option and its label cautions.
  • Indication (US label): management of anxiety disorders or short-term relief of anxiety symptoms. Efficacy was shown in controlled trials in outpatients whose diagnosis roughly matched generalised anxiety disorder. Formulation: oral tablet. [source: DailyMed, buspirone hydrochloride tablet label, Rev. 01/2026]
  • Label cautions (descriptive): contraindicated with MAOIs because of the risk of serotonin syndrome or raised blood pressure; starting it in someone on a reversible MAOI such as linezolid or intravenous methylene blue is also contraindicated. Patients should not drive or operate dangerous machinery until they know how the medicine affects them, should tell the physician about any medicines, alcohol or drugs they take, and should avoid large amounts of grapefruit juice; the label calls it prudent to avoid alcohol with buspirone. Buspirone is not a controlled substance. Studies showed no tolerance or physical or psychological dependence, but the label still asks physicians to check for a history of drug abuse and monitor closely. Because it has no cross-tolerance with benzodiazepines, it does not block benzodiazepine withdrawal. Most common adverse reactions: dizziness, nausea, headache, nervousness, lightheadedness and excitement. [source: DailyMed, buspirone hydrochloride tablet label, Rev. 01/2026]
  • Watch for: dizziness or nausea reported as "therapy making me worse". If a client has moved from a benzodiazepine to buspirone, withdrawal-type symptoms may still occur, because buspirone does not block them; pass such reports to the prescriber. If an MAOI or other serotonergic medicine is involved, the label lists serotonin syndrome features: mental-state changes (agitation, hallucinations, delirium), autonomic instability (fast heart rate, sweating, flushing, high temperature), neuromuscular changes (tremor, rigidity, jerking, overactive reflexes, poor coordination), seizures, and nausea, vomiting or diarrhoea. These need urgent medical help. [source: DailyMed buspirone label, Rev. 01/2026]

A4. SSRIs and SNRIs used for anxiety (brief)

  • Place in guidelines: for GAD, NICE says to offer an SSRI, considering sertraline first (1.2.23), then an alternative SSRI or an SNRI (1.2.24). For panic disorder, an SSRI licensed for panic disorder is preferred (1.3.25). Imipramine or clomipramine may be considered off-label if an SSRI is unsuitable or ineffective (1.3.26). Combination and augmentation only at step 4, with practitioners experienced in treatment-refractory anxiety (1.2.41–1.2.42). [source: NICE CG113]
  • Information NICE asks prescribers to give: likely benefits; side effects, withdrawal and interactions; possible early activation (more anxiety, agitation, sleep problems); the effect building over a week or more; continuing after remission; possible discontinuation symptoms such as dizziness, numbness, tingling, nausea, headache, sweating, anxiety and sleep disturbance; and bleeding risk with SSRIs, especially alongside NSAIDs or aspirin. [source: NICE CG113 1.2.28–1.2.29, 1.3.31–1.3.33]
  • Young adults: people under 30 should be warned about a small increased risk of suicidal thinking and self-harm, seen within 1 week and monitored weekly for the first month. [source: NICE CG113 1.2.30, 1.3.22] Full antidepressant labelling, including boxed suicidality warnings, belongs with the antidepressant entries. [synthesis]

A5. Medicines NICE advises against for these conditions

  • For GAD, do not offer an antipsychotic in primary care (1.2.27). For panic disorder, do not prescribe sedating antihistamines or antipsychotics (1.3.21). [source: NICE CG113] Labelling for other anxiolytic-type medicines (for example hydroxyzine) is not covered here. [uncertain]

B1. Medication, substance and attribution history

  • Purpose: know what the client takes and how they use it. Use at intake, and again whenever risk or prescriptions change.
  • Steps:
    1. Ask for every prescribed medicine, including as-needed ones, and for over-the-counter products, alcohol, cannabis, opioids (prescribed, cough medicines or street supply) and online-bought sedatives. The FDA asks patients to tell all their health professionals about all of these. [source: FDA 2020]
    2. Ask how the client actually uses the anxiolytic: on a schedule or as needed, before which situations, and whether they carry it "just in case". [synthesis]
    3. Ask what the client believes the medicine does, and how much of any improvement they credit to it compared with their own efforts. [synthesis, informed by Başoglu et al. 1994]
    4. Record the prescriber's name and contact details, and ask for written consent to liaise.
  • Example language (illustrative): "So I can plan therapy safely, I ask everyone about all their medicines and anything else they take to calm down or sleep, including alcohol. I won't tell you to change anything. That stays between you and your prescriber."
  • Watch for: vagueness about amounts, several prescribers, "borrowed" tablets, and opioid or alcohol co-use. Each is a reason to suggest a medical review (B2).

B2. Recognising when to suggest a medical review

  • Purpose: route medical questions to the right person in time.
  • Suggest a prompt or urgent review when you see [source for the signs: FDA 2020; MHRA 2019, 2021; NICE CG113]:
    • any severe withdrawal sign: seizures, confusion or delirium, hallucinations, catatonia, mania, psychosis, or new thoughts of killing oneself or someone else. Treat these as an emergency.
    • breathing difficulty, shallow breathing or heavy sedation, especially with opioids, alcohol or other sedatives. Treat this as an emergency.
    • signs of misuse or dependence: running out early, dose escalation, drug-seeking, supply from others.
    • a wish to stop or cut down. Route it to the prescriber, because abrupt stopping can cause dangerous withdrawal.
    • new agitation, worse sleep or suicidal thoughts after starting an SSRI or SNRI, especially under 30.
    • side effects that are getting in the way of therapy (memory problems, drowsiness, unsteadiness).
  • Steps: name what you have seen; explain why the prescriber needs to know; agree who will contact whom and by when; if the client agrees, send a short factual note yourself. For emergencies, use the client's crisis plan and emergency services. [synthesis]
  • Example language (illustrative): "What you're describing, feeling much sleepier and your breathing feeling shallow, is something the medicine's warnings say to report straight away. Can we ring your doctor's surgery together now?"
  • Watch for: reassurance that you are "overreacting"; record your concern and the plan.

B3. Psychoeducation about anxiolytics and therapy

  • Purpose: give accurate, balanced information that complements the prescriber's, using official sources.
  • Steps:
    1. Explain that NICE treats psychological therapy and medication as options within stepped care, with a choice at step 3. [source: NICE CG113]
    2. Show the client where to find their own Medication Guide or Patient Information Leaflet. The FDA says to read the Guide with each prescription. [source: FDA 2020; MHRA 2019]
    3. Describe official warnings neutrally, for example "the label warns that dependence can develop even when taken as prescribed". Then send any "so should I...?" question to the prescriber.
    4. Explain how therapy works: practising approaching fear, so that the learning stays with the client. [synthesis]
  • Example language (illustrative): "The leaflet is the official word on the medicine. Let's read the warnings section together, and write down any questions for your prescriber."
  • Watch for: health anxiety about side effects growing into avoidance of all treatment. Frame the information as a tool for choosing, not as a reason to fear.

B4. Supporting informed consent and shared decision-making

  • Purpose: help the client reach a choice that fits their values, with the prescriber.
  • Steps:
    1. Help the client list their goals, concerns (NICE names fear of addiction as a common concern to address), past treatment experience and preferences. [source: NICE CG113 1.2.45–1.2.46]
    2. Prepare questions for the prescriber, for example: What are the benefits and side effects? What does the label say about dependence and withdrawal? How will we review it? What happens if I want to come off it later?
    3. Practise the conversation if the client finds it hard to speak up with doctors.
    4. Afterwards, check what they understood. Clarify only by pointing back to the leaflet or the prescriber.
  • Example language (illustrative): "You've said your top worry is getting hooked. That's a fair question for Dr X. Shall we write it down exactly as you'd want to ask it?"
  • Watch for: the client deferring to you ("what would you do?"). Return the decision to the client and the prescriber.

B5. Conversations about adherence and ambivalence

  • Purpose: explore mixed feelings about medication without steering.
  • Steps:
    1. Reflect both sides: what the medicine gives them and what worries them.
    2. Ask about actual use compared with prescribed use, without judgement.
    3. If the client is not taking it as prescribed, or wants to change, help them take that to the prescriber. NICE stresses taking medication as prescribed, and the FDA says not to stop suddenly without a plan agreed with the prescriber. [source: NICE CG113 1.2.28; FDA 2020]
    4. Do not express approval or disapproval of the medicine. [synthesis]
  • Example language (illustrative): "Part of you wants to be off tablets, and part of you is scared of how you'd cope. Both make sense. Changing anything is something to plan with your prescriber, and it can be dangerous to stop some of these medicines suddenly. How would you like to raise it?"
  • Watch for: secret self-reduction, or skipping doses before sessions. Flag the safety issue and encourage contact with the prescriber.

B6. Monitoring and passing on side effects and warning signs

  • Purpose: use your frequent contact to make the prescriber's monitoring safer.
  • Steps:
    1. At the start of each session, run a brief check-in: sleep, daytime drowsiness, memory, mood, suicidal thoughts, any change in medicine use, alcohol or other substances. [synthesis]
    2. Compare with the official signs (A1–A4).
    3. Write a short factual note for the prescriber, with consent: what was observed, when, and what the client said. Do not interpret or recommend a medication action.
    4. Time notes to NICE's review points where useful (2–4 weeks for GAD, 2 weeks for panic disorder, 1 week for under-30s starting an SSRI or SNRI). [source: NICE CG113]
  • Example language (illustrative, note): "Since starting [medicine] two weeks ago, Ms A reports being more restless and sleeping less, and fleeting thoughts that life isn't worth it (no plan or intent; safety plan reviewed). I'm passing this on for your review."
  • Watch for: sedation affecting what the client takes in during sessions (forgetting homework, poor recall). The FDA lists memory problems among benzodiazepine effects. [source: FDA 2020]

B7. Coordinating exposure therapy with benzodiazepine use

  • Purpose: protect what the client learns in exposure, and plan sedative use openly with the prescriber.
  • What the sources say:
    • Proposed mechanisms by which benzodiazepines might blunt exposure include impaired attention and memory, fear extinction blocked in animal models, and cortisol suppression. Patients may also credit the drug for their gains, which could weaken generalisation. [source: Rosen et al. 2013, background]
    • Benzodiazepine-induced anterograde amnesia "has been proposed to interfere negatively with exposure-based psychotherapies". [source: Steenen et al. 2013, citing van Minnen et al. 2002]
    • In panic disorder with agoraphobia, patients on alprazolam made more medication attributions than those on placebo. Crediting medication rather than their own effort predicted worse withdrawal and loss of gains after the drug was stopped. [source: Başoglu et al. 1994] A companion trial in London and Toronto, Marks et al. 1993 (Br J Psychiatry 162:776–787), compared alprazolam and exposure alone and in combination; its findings are not summarised here.
    • In a reanalysis of a prolonged exposure trial for PTSD in women veterans and soldiers, benzodiazepine users did not respond worse to prolonged exposure. Benzodiazepine use was not randomised. [source: Rosen et al. 2013]
    • Summary: the evidence is mixed. Exposure can still help clients who take benzodiazepines, but attribution and as-needed use matter. [synthesis from the above]
  • Steps:
    1. Before exposure starts, map when and how the client uses the medicine around feared situations (B1).
    2. Explain, without advice on the medicine, that exposure works best when the client experiences the fear and learns it passes or is manageable. Anything used to "get through" can become a safety signal. [synthesis]
    3. Ask the client's consent to discuss timing and as-needed use with the prescriber before exposure starts. Any change is the prescriber's decision and must never be abrupt. [source: FDA 2020 on not stopping suddenly; synthesis]
    4. Do not make taking or not taking a dose a condition of an exposure task. Plan tasks around whatever regimen the prescriber has set. [synthesis]
    5. After each task, ask what the client thinks made the difference and draw out their own actions (B8).
    6. Exposure safety as standard: informed consent to exposure, screening for medical contraindications to strong arousal (refer for medical clearance where in doubt), graded and agreed steps, and the client's right to pause. Sedation that impairs alertness or judgement means the task should be postponed and the prescriber informed. [synthesis]
  • Example language (illustrative): "Some research suggests people do best long-term when they can see their own effort made the difference. I'd like to talk with Dr X about how your medicine fits around our practice tasks. Is that OK with you? I'm not asking you to change anything yourself."
  • Watch for: tablets carried or taken "just in case" during tasks, gains that disappear when the medicine is not on board, and very low distress during exposure because the client is sedated. Signs it is working: the client predicts and then tests outcomes, and credits their own coping.

B8. Attribution and self-efficacy work

  • Purpose: help the client credit their own coping. In one trial, crediting medication predicted relapse after it was stopped. [source: Başoglu et al. 1994]
  • Steps:
    1. After each success, ask: "What did you do that helped?" List the client's skills on a coping card in their own words.
    2. Ask the client to rate how much of the change came from their own efforts and how much from the medicine. Repeat the rating over time and discuss it, without disparaging the medicine.
    3. Run behavioural experiments that test the client's predictions about coping, within the regimen the prescriber has set.
    4. Review accumulated evidence of the client's own coping before any prescriber-planned change. [synthesis, built on Başoglu et al. 1994]
  • Example language (illustrative): "The medicine may take the edge off, and that's between you and Dr X. But you also stayed in the supermarket for twenty minutes and slowed your breathing. That part is yours."
  • Watch for: the client dismissing their own role ("it was just the pill"). It is working when their own-effort ratings rise and they show confidence about coping without tablets.

B9. Supporting a prescriber-led benzodiazepine discontinuation

  • Purpose: offer psychological support when the client and prescriber decide to reduce or stop a benzodiazepine. Withdrawal must be medically supervised. The therapist sets no schedule and gives no reduction advice. [source: FDA 2020]
  • What the sources say: in a randomised trial in panic disorder, 10 weeks of group CBT added to a taper programme led to more successful discontinuation than the taper alone. [source: Otto et al. 1993, abstract] A meta-analysis of three RCTs found higher discontinuation rates with CBT plus gradual tapering than with tapering alone, in the short and long term. The authors called for larger studies. [source: Takeshima et al. 2021] The FDA says there is no standard taper that fits everyone. The plan is the prescriber's, may be paused if withdrawal occurs, and needs monitoring. [source: FDA 2020]
  • Steps:
    1. Confirm that a plan exists and that the prescriber leads it. Ask the client to share any written plan if they wish.
    2. Prepare the client using official sources: the possible withdrawal symptoms, including protracted ones, and which signs need urgent help. [source: FDA 2020]
    3. Teach anxiety-management and interoceptive coping skills for withdrawal-related arousal. Keep this separate from any judgement about the medicine. [synthesis]
    4. Help the client tell withdrawal symptoms apart from returning anxiety by tracking symptoms, timing and context in a diary. Pass the findings to the prescriber. Diagnosing the cause is the prescriber's job. [synthesis]
    5. Plan contingencies with the client: who to call, and that the prescriber may pause or adjust the plan. [source: FDA 2020]
  • Example language (illustrative): "Your doctor is in charge of the reduction plan. My part is helping you handle the anxious feelings that can come up and keeping a record we can share. If anything on the 'urgent' list happens, we call straight away."
  • Watch for: severe withdrawal signs (emergency); suicidal thoughts; the client speeding up reductions on their own; and relapse into avoidance.

B10. Overdose and co-use safety

  • Purpose: reduce the risk of respiratory depression and overdose.
  • Steps:
    1. Screen for opioids, alcohol, gabapentinoids and other sedatives at every risk review. [source: FDA 2020; MHRA 2021]
    2. Share the official warning in plain words: combining these with opioids, alcohol or other depressants can slow breathing dangerously, and can kill.
    3. Encourage the client to tell every prescriber and pharmacist about everything they take. Explain the FDA advice to store the medicine securely and dispose of it properly. [source: FDA 2020]
    4. For clients with opioid use, encourage contact with their prescriber or addiction service. The FDA cautions against withholding opioid addiction medicines from people taking benzodiazepines; this is coordinated medically. [source: FDA 2020]
    5. Include emergency signs (trouble breathing, unresponsiveness, seizures) and emergency numbers in the safety plan. [source: FDA 2020]
  • Example language (illustrative): "This isn't a lecture. The leaflet itself warns that mixing this with alcohol or painkillers like codeine can affect breathing. Who else prescribes for you, and do they know about each other?"
  • Watch for: a pattern of escalating use or mixing substances. Refer for substance use assessment, as the FDA advises prescribers to do when a use disorder is suspected. [source: FDA 2020]

B11. Crisis and safety planning

  • Purpose: respond to suicidality and medical emergencies linked to medication.
  • Steps:
    1. Follow your service's standard suicide risk assessment and safety-planning protocol. Ask directly about suicidal thoughts, especially early in SSRI or SNRI treatment in under-30s and during any benzodiazepine reduction. [source: NICE CG113 1.2.30; FDA 2020 lists suicidal thoughts among severe withdrawal signs]
    2. Lethal-means counselling: agree safe storage of medicines, ask a trusted person to hold supplies if needed, and arrange disposal of unused medicine through a pharmacy. [source: FDA 2020 on locking up and disposing of medicines; synthesis]
    3. Write medical red flags into the plan (breathing problems, seizures, confusion, hallucinations) with emergency contacts.
    4. Inform the prescriber of any rise in risk, with consent where possible, or as your professional and legal duties require.
  • Example language (illustrative): "Let's add to your plan where your tablets are kept and who could look after them if things get bad."
  • Watch for: stockpiling, or ambivalent answers about storage.

B12. Collaborative care and liaison

  • Purpose: keep one coherent plan across the therapist, the prescriber and (in UK stepped care) primary or specialist services.
  • Steps: agree the liaison method and frequency at the start; share the psychological formulation and goals; notify the prescriber when exposure work begins and at milestones; refer to step 4 specialist services when NICE criteria apply (for example, significant symptoms persisting after two interventions in panic disorder, 1.3.35, or complex, treatment-refractory GAD, 1.2.37–1.2.38). [source: NICE CG113; synthesis on procedure]
  • Example language (illustrative, letter): "We begin graded exposure next week. Could we discuss how any as-needed medication is planned around it? No changes are suggested by me. I am raising it so we can coordinate."
  • Watch for: mixed messages to the client from different clinicians. Resolve these clinician-to-clinician.

B13. Integrating therapy before, during and after medication

  • Purpose: use each stage well.
  • Steps: Before: offer the choice of psychological treatment as NICE describes, and complete the formulation. During: deliver the full psychological protocol rather than "support only". NICE suggests adding high-intensity psychological intervention when response to medication is only partial (1.2.36). After: build a relapse-prevention plan, rehearse early warning signs, and offer booster sessions. NICE notes relapse is likely if effective GAD medication is stopped too early (1.2.33), so decisions about stopping go to the prescriber. [source: NICE CG113; synthesis on sequencing]
  • Example language (illustrative): "Whatever you and your doctor decide about medication, the skills you've built stay with you. Let's write your plan for spotting early signs."
  • Watch for: therapy ending at the same time as a medication change. Consider staggering them, after discussion with the prescriber. [synthesis]

B14. Special situations

  • Older adults and medical comorbidity: the MHRA lists people over 65 and those with respiratory, neurological or kidney disease as at higher risk of respiratory depression with pregabalin. Be alert to sedation and falls, and report them. [source: MHRA 2021; falls are synthesis]
  • Driving and machinery: the buspirone label tells patients not to drive or operate dangerous machinery until they know how the medicine affects them. It describes buspirone as less sedating than other anxiolytics, though drowsiness still occurs. [source: DailyMed buspirone label, Rev. 01/2026] Sedation from any anxiolytic is worth raising with the prescriber. [synthesis]
  • PTSD comorbidity: VA/DoD 2023 strongly recommends against benzodiazepines for PTSD. If a client is taking one, coordinate as in B7 rather than advising. [source: health.mil 2025]
  • Pregnancy, breastfeeding, adolescents: not covered in this guide. Route to the prescriber. [uncertain]
  • Example language (illustrative): "You mentioned feeling drowsy when you drive. That's worth telling your prescriber soon; would you like to call from here?" [synthesis]
  • Watch for: sedation, falls or breathing problems in the higher-risk groups above; pass them on to the prescriber, the same day if severe. [synthesis]

5. Handling problems

The published sources give no guidance for therapists on these problems. Everything below is [synthesis], except where a source is tagged.

  • The client asks, "Should I stop my tablets?" Do not answer the medical question. Say it is a decision for them and their prescriber, and that stopping some of these medicines suddenly can be dangerous [source: FDA 2020]. Then help them prepare the questions and book the appointment.
  • The client has already cut down or stopped on their own. Check for withdrawal and severe signs (A1). Severe signs mean emergency care. Otherwise, encourage same-day or next-day contact with the prescriber and, with consent, make contact yourself. Stay non-judgemental. Shame drives concealment.
  • The client is escalating or obtaining supply elsewhere. Name the pattern, link it to the official warnings, and encourage review with the prescriber and a substance use assessment [source: FDA 2020; MHRA 2019]. Screen for opioid and alcohol co-use (B10). Record what was said and the plan.
  • Stuck exposure: gains appear only "on" the medicine. Review attribution (B8) and how as-needed use is timed around tasks. Raise this coordination question with the prescriber (B7). Do not set a medicine condition yourself.
  • Very low distress during exposure because the client is sedated. Postpone the task if alertness or judgement is impaired, and let the prescriber know about the sedation. Plan tasks in line with the regimen the prescriber has set.
  • Overwhelm during a prescriber-led reduction. Slow the pace of exposure, prioritise stabilisation and coping skills, and keep a symptom diary for the prescriber. The FDA notes the prescriber may pause the plan if withdrawal occurs [source: FDA 2020]. Never suggest a pace yourself.
  • Withdrawal or relapse? Do not decide. Describe the symptoms, timing and context, and pass them on. Protracted withdrawal can last months [source: FDA 2020], so validate the experience while the prescriber assesses it.
  • Non-adherence to the medicine. Explore it with curiosity (B5) and route it to the prescriber.
  • Non-adherence to therapy homework because of sedation or poor memory. Use written summaries, shorter tasks and phone reminders, and pass the cognitive effects on to the prescriber [source: FDA 2020 lists memory problems].
  • Resistance: "Therapy can't work while I'm on these." Share that one PTSD exposure study found benzodiazepine users still benefited from prolonged exposure [source: Rosen et al. 2013]. Keep the focus on what the client can learn.
  • Resistance the other way: "Pills are cheating, I'll stop them myself." Validate the value they place on independence. Explain the safety reasons to plan any change with the prescriber [source: FDA 2020].
  • Rupture: the client feels judged about their medicine, or that you are taking the doctor's side. Name it, apologise for any implied judgement, and restate your role: you neither promote nor oppose the medicine. Repair by collaborating openly on what goes to the prescriber.
  • Conflicting messages from clinicians (for example, the prescriber is happy with ongoing use while you are concerned about attribution). Resolve this clinician-to-clinician, document it, and do not put the client in the middle. Seek supervision.
  • The prescriber is unresponsive to a safety concern. Escalate through practice or service channels, consult your supervisor, and follow your professional code. Emergencies go to emergency services directly.
  • The client is using an unprescribed or online-bought "benzo" or pregabalin. Explain the official risks (overdose with opioids or alcohol; in the UK, possession without a prescription is illegal [source: MHRA 2019]). Encourage medical and substance-service contact, and build in harm-reduction safety planning without means detail.
  • Comorbid PTSD on a benzodiazepine. Coordinate as in B7 and B14. Do not delay trauma-focused therapy solely because of benzodiazepine use, given the Rosen et al. 2013 findings [source], but plan it jointly with the prescriber.

Sources

← Previous · IX-004Mood stabilisers including lithiumNext · IX-006 →Stimulants